Please use this identifier to cite or link to this item:
|Title:||Characterization of neurotensin(6-13) from an hepatic fibrolamellar carcinoma.|
|Authors:||Read, D M;Shulkes, Arthur;Fernley, R;Simpson, R|
|Affiliation:||Department of Surgery, University of Melbourne, Austin Hospital, Victoria, Australia|
|Citation:||Peptides; 12(4): 887-92|
|Abstract:||Neurotensin(6-13) has been isolated and sequenced as the major form of neurotensin-like immunoreactivity (NTLI) in a human hepatic fibrolamellar carcinoma. Circulating NTLI in the patient, especially C-terminal, was very high. In additional studies, NT(6-13) was synthesized and compared with the purified tumor NTLI by HPLC analysis and by testing stability in plasma in vitro. These methods confirmed that the tumor NTLI was identical to NT(6-13). Since the metabolic clearance rate of synthetic NT(6-13) in sheep was 30-fold higher than NT(1-13), it suggests that the elevated plasma levels are the result of impaired clearance and/or markedly elevated production.|
|Internal ID Number:||1664950|
Amino Acid Sequence
Chromatography, High Pressure Liquid
Molecular Sequence Data
Neuropeptides.blood.chemistry.isolation & purification
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.